Allstate
ALL
$247.88
+3.46%
Allstate is one of the largest US property-casualty insurers, writing personal auto (its largest revenue line), homeowners, and other insurance products distributed primarily through roughly 6,000 exclusive agents across North America. Its competitive identity rests on the Allstate agency network and brand in personal lines, complemented by the Protection Services segment (Allstate Protection Plans, dealer services, identity protection) that adds fee-based, less catastrophe-exposed earnings. The current investor narrative centers on a powerful underwriting recovery: after a multi-year stretch of auto profitability pressure, sharply higher premiums and a benign catastrophe year have driven net income to $3.27B in Q2 2026 versus $2.11B a year earlier, with the stock up roughly 27% over the past year. Debate now hinges on whether this earnings surge is a durable underwriting-margin story or a cyclical peak, especially with the shares having pulled back from their summer highs and sell-side ratings turning more mixed.…
ALL
Allstate
$247.88
Related headlines
Investment Opinion: Should I buy ALL Today?
Rating: Hold. The core thesis is that Allstate is a high-quality franchise trading at a deep discount (5.38x trailing PE, 1.78x PB) with an exceptional 33.59% ROE, but the earnings base is cyclically elevated and the market is correctly pricing in normalization (forward PE of 8.82x above trailing). The analyst consensus of 'buy' with a $269.27 average target implies only +8.6% upside, which is modest relative to the downside risk to the $191 low target. This is a fairly valued to slightly undervalued stock, not a compelling bargain.
Supporting evidence: (1) Revenue growth of 12.39% YoY in Q2 2026 is healthy and accelerating; (2) net margin of 17.60% is strong but likely peak-cycle given the 3.66% trough in Q1 2025; (3) TTM free cash flow of $12.249B and a 11.21% payout ratio provide ample capital return capacity; (4) the 2.12% dividend yield and $1.051B quarterly buyback are shareholder-friendly; (5) the 0.245 debt-to-equity ratio is conservative. Against this, the forward PE inversion and the August downgrades suggest the easy money has been made.
Key risks that could invalidate the thesis: a normal-to-active hurricane season compressing margins, regulatory rate approval delays, and auto frequency/severity re-acceleration. This Hold would upgrade to Buy if the stock pulls back toward the $225–230 support zone (implying ~7–9% downside) while underwriting margins hold, or if Q3 2026 results show margin durability through a normal cat quarter. It would downgrade to Sell if net margin falls below 12% for two consecutive quarters or if the stock breaks below the $225.66 September low on volume. Valuation verdict: fairly valued to modestly undervalued relative to history, but the discount is justified by cyclical earnings risk.
Sign up to view all
ALL 12-Month Price Forecast
The risk/reward is balanced: the stock is cheap on trailing metrics but the forward PE inversion correctly anticipates earnings normalization, and the analyst consensus target offers only modest upside. The 33.59% ROE and $12.249B FCF are genuine strengths, but the 19.36% max drawdown and August downgrades show sentiment is fragile. I would upgrade to bullish if Q3 2026 results demonstrate net margin above 15% through a normal cat quarter, or if the stock pulls back to the $225–230 support zone with fundamentals intact. I would downgrade to bearish if net margin falls below 12% or if the stock breaks below $225.66 on elevated volume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Allstate's 12-month outlook, with a consensus price target around $269.27 and implied upside of +8.6% versus the current price.
Average Target
$269.27
0 analysts
Implied Upside
+8.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$191 - $340
Analyst target range
Coverage is broad, with 22 analysts and a consensus recommendation of "buy" (mean rating 2.44 on a scale where lower is more bullish). The average target price of $269.27 implies roughly +8.6% upside from the current $247.88, a moderate rather than aggressive bullish stance. Consensus estimates call for EPS averaging $26.61 (range $23.70–$28.77) on revenue of about $64.06B, which frames the target as consistent with steady execution rather than a major re-rating.
The target range is wide — $191.00 to $340.00 — signaling meaningful disagreement about the durability of the earnings cycle. The high target of $340 would require roughly 37% upside and likely assumes sustained underwriting margins, multiple expansion toward peer levels, and continued capital return; the low target of $191 sits about 23% below the current price and appears to price in margin compression or a return to heavier catastrophe losses. Recent institutional actions lean cautious: Citigroup cut to Sell from Neutral and Keefe, Bruyette & Woods downgraded to Underperform from Market Perform in August 2026, while Argus moved to Hold from Buy, offset by reiterated Outperform/Overweight ratings from Mizuho, JP Morgan, and BMO. The dispersion and the drift toward downgrades suggest conviction is thinning even as the consensus headline remains positive.
Drowning in data?
Find the real signal!
Bulls vs Bears: ALL Investment Factors
The bull case currently has stronger evidence: the earnings inflection is quantifiable (net income up 55% YoY, gross margin up 10.4 points), the balance sheet is conservative (D/E 0.245), and the valuation is undeniably cheap (5.38x trailing PE, 1.78x PB). However, the bear case is not weak — the forward PE inversion above the trailing PE is a clear signal that the market expects mean reversion, and the August downgrades from Citigroup and KBW suggest sophisticated investors are positioning for exactly that. The single most important tension is whether the current underwriting margin reflects durable rate adequacy or a benign catastrophe year; if catastrophe losses normalize to historical levels, the earnings base could compress materially and validate the discount. Conversely, if margins hold through a normal cat year, the PE and PB have substantial room to re-rate toward historical midpoints.
Bullish
- Earnings inflection is dramatic: Q2 2026 net income reached $3.273B versus $2.109B a year earlier, lifting net margin to 17.60% from 12.75%. Gross margin expanded to 34.75% from 24.37%, showing underwriting rate increases are flowing through to the bottom line.
- Valuation is deeply discounted: Trailing PE of 5.38x and forward PE of 8.82x are far below typical P&C peer multiples in the low-to-mid teens. PB of 1.78x sits near the low end of its historical 1.67x–2.48x band despite a 33.59% ROE.
- Revenue growth accelerating: Q2 2026 revenue of $18.596B grew 12.39% YoY, accelerating from $16.941B in Q1 2026 and $16.590B in Q4 2025. The multi-quarter progression shows consistent top-line momentum from rate and policy growth.
- Fortress balance sheet and cash flow: Debt-to-equity is a conservative 0.245 and TTM free cash flow is $12.249B. Q2 operating cash flow of $2.634B comfortably covered $310M of dividends and $1.051B of buybacks, with a modest 11.21% payout ratio.
Bearish
- Earnings may be cyclical peak: The forward PE of 8.82x exceeds the trailing 5.38x, an unusual inversion implying consensus expects EPS of ~$26.61 versus a trailing base inflated by the current surge. The market is explicitly pricing in earnings normalization.
- Catastrophe-loss dependence: The earnings surge coincides with a 'quiet catastrophe year' per Motley Fool (July 2026). Q1 2026 net margin dipped to 14.51% from 23.10% in Q4 2025 on seasonal catastrophe activity, showing how quickly margins can compress.
- Analyst downgrades are mounting: Citigroup cut to Sell and Keefe, Bruyette & Woods downgraded to Underperform in August 2026, while Argus moved to Hold from Buy. This drift toward downgrades signals thinning conviction despite the positive consensus headline.
- Momentum is decelerating: The stock is down 2.73% over the past month and 0.81% over three months, with relative strength of -3.95 and -3.50 versus SPY. The 19.36% max drawdown from the July/August highs shows the pullback was sharp.
ALL Technical Analysis
Allstate is in a sustained uptrend that has recently transitioned into a high-level consolidation. The stock is up 27.20% over the past year and 21.62% year-to-date, and at $247.88 it sits at roughly 66.6% of its 52-week range of $188.08 to $277.22 — closer to the highs than the lows, but meaningfully below the peak. That positioning suggests momentum remains intact while the stock digests a large advance rather than breaking down; the 19.36% max drawdown shows the pullback from the July/August highs was sharp enough to shake out weak hands.
Short-term momentum is decelerating and diverging from the longer-term trend. The stock is down 2.73% over the past month and 0.81% over three months, versus a 1-year gain of 27.20%, producing relative strength of -3.95 versus SPY over one month and -3.50 over three months even as 1-year relative strength remains a strong +11.67. The recent tape, however, shows a sharp reversal: from a September 22 close of $229.50 the stock has rallied to $247.88, including a 3.46% single-day jump on the latest session on volume of about 3.5 million shares. That pattern — a multi-month pullback followed by a forceful bounce — is more consistent with mean reversion off support than with trend failure.
Key levels are well defined. Resistance sits at the 52-week high of $277.22, roughly 11.8% above the current price; a breakout there would confirm the uptrend has resumed and likely invite momentum buyers. Support rests at the 52-week low of $188.08, about 24.1% below current levels, with the September low near $225.66 acting as a nearer-term floor. The reported beta of 0.138 implies the stock has historically moved with very little sensitivity to the broad market — unusual for an insurer but consistent with a low-correlation, defensive earnings stream — which supports larger position sizing on a volatility-adjusted basis, though the 19.36% max drawdown and 3.08 short ratio argue for respecting event risk around earnings and catastrophe-loss disclosures.
Beta
0.14
0.14x market volatility
Max Drawdown
-19.4%
Largest decline past year
52-Week Range
$188-$277
Price range past year
Annual Return
+27.2%
Cumulative gain past year
| Period | ALL Return | S&P 500 |
|---|---|---|
| 1m | -2.7% | +0.2% |
| 3m | -0.8% | +2.9% |
| 6m | +14.7% | +8.4% |
| 1y | +27.2% | +14.9% |
| ytd | +21.6% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALL Fundamental Analysis
Revenue is growing at a healthy clip. Q2 2026 revenue reached $18.596B, up 12.39% year over year from $16.546B in Q2 2025, and the multi-quarter progression ($16.263B in Q1 2025, $16.546B in Q2 2025, $17.061B in Q3 2025, $16.590B in Q4 2025, $16.941B in Q1 2026, $18.596B in Q2 2026) shows acceleration into the most recent quarter. The Protection Services segment contributed $915M, a small but fee-based slice of the mix, while the core auto and homeowners books are clearly driving the top line through rate increases and policy growth. For the investment case, double-digit revenue growth combined with improving underwriting is the engine behind the earnings re-rating.
Profitability has inflected dramatically. Q2 2026 net income was $3.273B on a 17.60% net margin, versus $2.109B and a 12.75% net margin in Q2 2025, and gross margin expanded to 34.75% from 24.37% a year earlier. The quarterly net margin path — 3.66% in Q1 2025, 12.75% in Q2 2025, 21.96% in Q3 2025, 23.10% in Q4 2025, 14.51% in Q1 2026, 17.60% in Q2 2026 — shows the company has moved from marginal profitability to mid-to-high-teens returns, with the Q1 2026 dip reflecting seasonal catastrophe activity. Operating margin of 19.80% and a 33.23% gross margin are strong for personal-lines P&C, where underwriting margins are inherently volatile; the key question is how much of this reflects sustainable rate adequacy versus a light catastrophe year.
Financial health is solid and cash generation is robust. Debt-to-equity is a conservative 0.245, ROE is an exceptional 33.59%, and ROA is 8.68%, reflecting both strong earnings and the insurer's leveraged balance-sheet model. Free cash flow TTM is $12.249B, with Q2 2026 operating cash flow of $2.634B and FCF of $2.591B, comfortably covering $310M of dividends and $1.051B of buybacks in the quarter. The low current ratio of 0.37 is typical for insurers, whose liabilities are reserves rather than trade payables, and the 2.12% dividend yield with a modest 11.21% payout ratio leaves ample room for continued capital return.
Quarterly Revenue
$18.6B
2026-06
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
34.8%
Latest Quarter
Free Cash Flow
$12.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALL Overvalued?
Because Allstate is solidly profitable (Q2 2026 net income of $3.273B), the PE ratio is the appropriate primary metric. The trailing PE of 5.38x is extraordinarily low, and the forward PE of 8.82x sits above it — an unusual inversion that reflects the market expecting forward EPS of roughly $26.61 (consensus) against a trailing base inflated by the current earnings surge. The gap implies investors are pricing in some normalization of underwriting earnings rather than extrapolating the current run-rate, a cautious stance for a stock whose earnings have inflected so sharply.
Against its sector, the valuation looks cheap on most measures. A PE of 5.38x trailing and 8.82x forward compares favorably to typical P&C peer multiples in the low-to-mid teens, and the 0.82x PS ratio and 1.78x PB ratio are modest for a franchise with 33.59% ROE. EV/EBITDA of 4.36x and EV/Sales of 0.92x are similarly low, while the 2.12% dividend yield and 11.21% payout ratio suggest the market is not paying up for capital return. The discount appears justified in part by the cyclicality of catastrophe losses and the risk that current margins are peak-cycle, but the magnitude of the discount — particularly versus a 15.47% net margin — leaves room for re-rating if underwriting discipline holds.
Historically, Allstate's own valuation band has been wide. The PE ratio troughed near 3.58x in Q4 2025 and 4.70x in Q2 2026, versus 24.17x in Q1 2025 and negative readings during the 2022–2023 loss years, while PB has ranged from about 1.67x to 2.48x over the past several years and now sits at 1.78x — near the lower end of that band. The stock is therefore not priced for optimism on a book-value basis; instead, the market appears to be treating the current earnings level as cyclically elevated. If catastrophe losses normalize and margins prove durable, both the PE and PB could expand toward historical midpoints, but a reversion in underwriting results would validate the current discount.
PE
5.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
4.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the cyclicality of underwriting earnings. The Q2 2026 net margin of 17.60% and gross margin of 34.75% are exceptionally strong for personal-lines P&C, but the quarterly path shows how volatile this can be: net margin fell from 23.10% in Q4 2025 to 14.51% in Q1 2026 on seasonal catastrophe activity. Revenue is concentrated in personal auto and homeowners, both of which are exposed to frequency/severity trends and regulatory rate approval risk. The low current ratio of 0.37 is normal for insurers but reflects the reserve-heavy liability structure; a adverse reserve development would hit book value directly. Finally, the earnings surge depends on continued premium growth — if rate increases moderate while loss costs stay elevated, the margin tailwind reverses.
Market and competitive risks include valuation compression if the market's normalization thesis proves correct. The forward PE of 8.82x sitting above the trailing 5.38x means the market is already discounting an earnings decline; if that decline is steeper than expected, the stock could de-rate further. The beta of 0.138 implies very low market correlation, which is defensive but also means the stock won't benefit much from a broad market rally. Competitive pressure from direct-to-consumer insurers and larger peers could limit pricing power as the industry cycle turns. Recent news highlights the catastrophe-year dependence — a single active hurricane season could erase the margin gains. The August 2026 downgrades from Citigroup (to Sell) and KBW (to Underperform) are a concrete signal that sell-side conviction is eroding.
Worst-case scenario: a return to elevated catastrophe losses combined with auto frequency normalization and regulatory pushback on rate increases would compress underwriting margins back toward the 2024–early-2025 levels, when Q1 2025 net margin was just 3.66%. In that scenario, the stock could retest its 52-week low of $188.08, which is 24.1% below the current $247.88. The analyst low target of $191 is roughly consistent with this downside (~23%). A more severe outcome — a major hurricane hitting a densely populated metro area plus adverse reserve development — could push the stock below the 52-week low, implying a loss of 25–30% from current levels. The 19.36% max drawdown already experienced shows the stock is capable of sharp declines when sentiment shifts.
FAQ
The most severe risk is catastrophe-loss exposure: the earnings surge coincides with a quiet cat year, and Q1 2026 net margin already dipped to 14.51% from 23.10% on seasonal activity. A major hurricane could erase much of the margin gain. Second is earnings cyclicality — the forward PE inversion signals the market expects normalization, and a return to the 3.66% net margin seen in Q1 2025 would validate that view. Third is analyst sentiment deterioration, with Citigroup cutting to Sell and KBW to Underperform in August 2026. Fourth is competitive and regulatory pressure on rate increases in key states. Ranked by severity: catastrophe risk first, earnings normalization second, sentiment third, regulatory fourth.
The 12-month forecast has three scenarios: bull (25% probability, $290–$340) if underwriting margins prove durable and multiple expands toward peer levels; base (55% probability, $255–$280) if earnings normalize modestly and the stock trades around the analyst average target of $269.27; and bear (20% probability, $188–$210) if catastrophe losses return and margins compress toward single digits. The base case is most likely, anchored by consensus EPS of $26.61 and revenue of $64.06B, implying the stock trades roughly flat to modestly higher from the current $247.88. The key assumption is that net margin settles in the 13–15% range rather than reverting to the 2024–early-2025 trough.
ALL appears undervalued on trailing metrics but fairly valued on forward metrics. The trailing PE of 5.38x, PS of 0.82x, and PB of 1.78x are all well below typical P&C peer multiples in the low-to-mid teens, and PB sits near the low end of its historical 1.67x–2.48x band. However, the forward PE of 8.82x is higher than the trailing PE — an unusual inversion that implies consensus expects EPS of ~$26.61 versus a trailing base inflated by the current earnings surge. The market is therefore paying a fair price for normalized earnings, not a discount. If underwriting margins prove durable, the stock could re-rate toward peer multiples; if margins compress, the current discount is justified.
From a risk/reward perspective, ALL is a moderate buy at best. The stock trades at 5.38x trailing earnings and 1.78x book — deeply discounted versus P&C peers — with a 33.59% ROE and $12.249B in TTM free cash flow. However, the forward PE of 8.82x sits above the trailing PE, meaning the market expects earnings to decline from the current $3.273B quarterly run-rate, and the analyst average target of $269.27 implies only +8.6% upside. The biggest downside risk is a return to elevated catastrophe losses, which could push the stock toward the $191 analyst low target (~23% downside). It is a good buy for value investors with a 12–18 month horizon who can tolerate cat-driven volatility, but not a compelling bargain for short-term traders given the recent momentum deceleration.
ALL is better suited for medium-to-long-term holding (12–18 months minimum) than short-term trading. The beta of 0.138 means low market correlation and defensive characteristics, but the 19.36% max drawdown and 3.08 short ratio show the stock can move sharply around earnings and catastrophe disclosures. The 2.12% dividend yield and 11.21% payout ratio provide income support, and the $12.249B TTM free cash flow funds consistent buybacks. Earnings visibility is moderate — underwriting results are inherently volatile — so short-term traders face event risk around quarterly cat-loss disclosures. A minimum 12-month holding period allows time for the underwriting cycle to play out and for capital return to compound.
